Although gout is a common disease that may have serious consequences, numerous studies show that gout is often misdiagnosed and that its management is suboptimal. New evidence-based guidelines for the management of gout from the European League Against Rheumatism (EULAR), published on July 25, 2016, have been developed in the hopes of remedying these issues.
Celecoxib is superior to acetaminophen in relieving pain in patients with chronic, nonspecific low back pain, Canadian investigators have found.
The first biosimilar was approved in the United States in 2015, but this category of drugs is still fairly misunderstood, according to Jim M. Koeller, MS, Professor, College of Pharmacy, the University of Texas at Austin.
Joint-specific differences in epigenetic imprinting and gene expression suggest that disease mechanisms in rheumatoid arthritis (RA) may vary from joint to joint, which may possibly explain some of the varying drug responses among patients with RA, researchers have found.
- Portable Device Offers Easier, Cost-Effective Approach to Gout Diagnosis
- Efficacy and Safety Maintained for Up to 5 Years with Tocilizumab Therapy
- First Ever Treatment Guidelines for Managing Rheumatologic Manifestations of Sjögren’s Syndrome
- Short-Term Use of Soft Lateral Wedge Arch Support Significantly Reduces Pain in Patients with Knee Osteoarthritis
London, United Kingdom—More than one-third of patients with rheumatoid arthritis (RA) who are still sexually active experience sexual dysfunction. And yet, this topic is rarely, if ever, addressed in discussions with rheumatologists, according to the investigators of a study presented at the 2016 European League Against Rheumatism Annual Congress.
Patients with rheumatoid cachexia had significant improvement in lean muscle mass with creatine supplementation but no gains in strength or function in a new, small, placebo-controlled clinical trial.
- Growing Burden of Arthritis in the United States
- Patients with Lupus at Risk for End-Stage Renal Disease
London, United Kingdom—Monitoring antidrug antibody formation in those receiving biologic disease-modifying antirheumatic drugs can inform treatment decisions in patients with rheumatic diseases. In particular, patients who developed antibodies to infliximab (Remicade) cross-reacted with the infliximab biosimilar CT-P13—marketed as Remsima or Inflectra—according to data from a multicenter, controlled study of patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA) presented at the 2016 European League Against Rheumatism Annual Congress.
London, United Kingdom—Inflammatory bowel disease (IBD) is often associated with psoriasis, psoriatic arthritis (PsA), and ankylosing spondylitis (AS), explained Stefan Schreiber, MD, Christian-Albrechts-University, Kiel, Germany. The risk for Crohn’s disease is approximately 4 times higher in patients with psoriasis, compared with the general population; it is even higher in patients with PsA and AS.
- 1
- 2
Page 1 of 2
Results 1 - 10 of 17
Results 1 - 10 of 17
